Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Avacta Group Share News (AVCT)
AVCT Share
Price
AVCT Share
News
AVCT Share
Chat9
AVCT Share
Trades93
AVCT
Live RNS
AVCT Share
Charts
AVCT Level 2
Console
AVCT Live
Share Price
AVCT Broker
Ratings
AVCT Directors
Deals
AVCT Financial
Diary
AVCT
Fundamentals
AVCT Short
Positions
AVCT
Media
AVCT Company
Research
AVCT Company
Timeline
Avacta Group Information
Share Price Information for Avacta Group (AVCT)
Share Price is delayed by 15 minutes
Get Live Data
71.50
1.50 (2.14%)
Bid:
70.00
Ask:
73.00
Spread:
3.00 (4.286%)
Market Cap:
£325.40m
Last checked at -
Last checked at 
Intraday Avacta Group Share Chart
Avacta Group News
8 Mar 2021
Avacta confirms efficacy of test on variant Covid-19 strains
(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test de...
24 Feb 2021
TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End
TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End
24 Feb 2021
AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone
AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone
22 Feb 2021
AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans
AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans
22 Feb 2021
Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test
Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test
22 Feb 2021
Avacta clarifies reports on potential use of its Covid-19 test
(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the U...
22 Feb 2021
LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears
LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears
18 Feb 2021
IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000
IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000
Follow the stocks
